R
Roohi Nigar
Researcher at Liaquat University of Medical and Health Sciences
Publications - 9
Citations - 192
Roohi Nigar is an academic researcher from Liaquat University of Medical and Health Sciences. The author has contributed to research in topics: Quercetin & Medicine. The author has an hindex of 3, co-authored 5 publications receiving 29 citations.
Papers
More filters
Journal ArticleDOI
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
Francesco Di Pierro,Giuseppe Derosa,Pamela Maffioli,Alexander Bertuccioli,Stefano Togni,Antonella Riva,Pietro Allegrini,Amjad Khan,Amjad Khan,Saeed Khan,Bilal Ahmad Khan,Naireen Altaf,Maria Zahid,Ikram Din Ujjan,Roohi Nigar,Mehwish Imam Khushk,Maryam Phulpoto,Amanullah Lail,Bikha Ram Devrajani,Sagheer Ahmed +19 more
TL;DR: In this article, a prospective, randomized, controlled, and open-label study, a daily dose of 1000 mg of quercetin was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease.
Journal ArticleDOI
Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
Mohammad Tahir Yousafzai,Mohammad Tahir Yousafzai,Sultan Karim,Sonia Qureshi,Momin Kazi,Hina Memon,Amber Junejo,Zohra Khawaja,Najeeb Ur Rehman,Muhammad Sajid Ansari,Rafey Ali,Ikram Uddin Ujjan,Heera Mani Lohana,Naveed Masood Memon,Mudassar Hussain,Roohi Nigar,Naor Bar-Zeev,Farah Naz Qamar +17 more
TL;DR: In this paper, the effectiveness and impact of the typhoid conjugate vaccine Typbar-TCV against S Typhi among children in an outbreak setting of extensively drug-resistant (XDR)-S Typhi in Pakistan was investigated.
Journal ArticleDOI
Quercetin Phytosome® as a potential candidate for managing COVID-19.
Francesco Di Pierro,Amjad Khan,Alexander Bertuccioli,Pamela Maffioli,Giuseppe Derosa,Saeed Khan,Bilal Ahmad Khan,Roohi Nigar,Ikram Din Ujjan,Bikha Ram Devrajani +9 more
TL;DR: Taking into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercet in Phytosome®, should be considered a possible candidate to clinically face COVID-19.
Journal ArticleDOI
Quercetin Phytosome R as a potential candidate for managing COVID-19
F. Di Pierro,Amjad Khan,Alexander Bertuccioli,Pamela Maffioli,Giuseppe Derosa,Saeed Khan,Bilal Ahmad Khan,Roohi Nigar,Ikram Din Ujjan,Bikha Ram Devrajani +9 more
TL;DR: A phospholipid delivery form of quercetin was recently tested in humans to evaluate a possible improvement in oral bioavailability after hydrolysis of the conjugated form (mainly glucuronide) found in human plasma, the pharmacokinetics results have demonstrated an increased bioavailability rate by about 20-fold for total quercETin this paper.
Quercetin Phytosome® as a potential drug for Covid-19
F. Di Pierro,Amjad Ali Khan,Alexander Bertuccioli,Pamela Maffioli,Giuseppe Derosa,Shifa Khan,Bilal Ahmad Khan,Roohi Nigar,Ikram Din Ujjan,B. R. Devraian +9 more
TL;DR: Taking into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercet in Phytosome®, should be considered a possible candidate to clinically face COVID-19.